NCT04594421 is a clinical trial in Peritonitis, sponsored by Peking University First Hospital.

Who is sponsoring NCT04594421?

NCT04594421 is sponsored by Peking University First Hospital.

What condition does NCT04594421 study?

NCT04594421 studies Peritonitis.

Is NCT04594421 still recruiting?

NCT04594421 is currently status unknown. Last updated 8 December 2021.

Last reviewed 2021-12-08 · How we verify

NCT04594421

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Change Trend of Effluent Eosinophil During Peritoneal Dialysis-Related Peritonitis

Status unknown Last updated 8 December 2021

What this trial tests

trial in Peritonitis in 100 participants. Status unknown.

Timeline

18 February 2021

Primary endpoint
31 December 2023

1 April 2024

Quick facts

Lead sponsor	Peking University First Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	18 February 2021
Primary completion	31 December 2023
Estimated completion	1 April 2024
Sites	1 location across China

Conditions studied

Peritonitis — all drugs for Peritonitis →

Sponsor

Peking University First Hospital

Who can join

14 and older, any sex, with Peritonitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A multi-center prospective cohort study will be conducted to explore the change trend of eosinophil in peritoneal dialysis effluent during peritoneal dialysis-associated peritonitis, and to explore the relationship between eosinophil increase, peritonitis severity and antibiotic use. This study will provide evidence for routine eosinophil testing

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Peritonitis

Currently open trials in the same condition.

NCT04604730 — Role of Protective Stoma After Primary Anastomosis for Generalized Peritonitis Due to Perforated Diverticulitis · NA · recruiting

Other Peking University First Hospital trials

Trials by the same sponsor.

NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
NCT07517276 — TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index · Phase 2 · not yet recruiting
NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
NCT07464119 — A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy · NA · not yet recruiting
NCT07460843 — Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04594421 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University First Hospital
Last refreshed: 8 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04594421.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing